Denosumab does not delay nonvertebral fracture healing

Denosumab does not delay nonvertebral fracture healing
Denosumab does not appear to delay fracture healing or contribute to other complications when used to treat postmenopausal women with osteoporosis, according to research published in the Dec. 5 issue of The Journal of Bone & Joint Surgery.

(HealthDay)—Denosumab does not appear to delay fracture healing or contribute to other complications when used to treat postmenopausal women with osteoporosis, according to research published in the Dec. 5 issue of The Journal of Bone & Joint Surgery.

To examine the impact of administration on , Silvano Adami, M.D., Ph.D., of the University of Verona in Italy, and colleagues conducted a pre-planned analysis of the three-year, placebo-controlled FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every Six Months) study. The study included (aged 60 to 90 years) with who received either 60 mg of denosumab (3,902 ) or placebo (3,906 women) subcutaneously once every six months for three years.

The researchers identified 386 nonvertebral fractures among 303 denosumab-treated women and 465 fractures among 364 placebo-treated women, of which 199 fractures were treated surgically (79 and 120 in the denosumab and placebo groups, respectively). Seven individuals experienced delayed healing, including one with subsequent nonunion; two of these women were treated with denosumab and five received placebo. None of the women who experienced delayed fracture healing or nonunion had received denosumab within six weeks of the fracture. In 2 percent of the denosumab group and 5 percent of the placebo group there was a complication associated with the fracture or intervention.

"In the thirty-six-month FREEDOM trial, there was no evidence that denosumab treatment delayed healing or contributed to complications related to a nonvertebral fracture or its management," the authors write. "However, since the exact timing of completion of fracture healing could not be determined, it remains theoretically possible that denosumab might delay or speed fracture healing."

The study was funded by Amgen, which developed denosumab. Several authors disclosed financial ties to an entity in the biomedical arena.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Denosumab delayed time to first skeletal-related side effect

Dec 10, 2010

For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San ...

Recommended for you

Where Ebola battles are won

4 hours ago

(HealthDay)—Four hospitals that are home to advanced biocontainment facilities have become America's ground zero in the treatment of Ebola patients.

Depression tied to worse lumbar spine surgery outcomes

6 hours ago

(HealthDay)—Depressive symptoms are associated with poorer long-term outcome in patients undergoing surgery for lumbar spinal stenosis (LSS), according to research published in the Oct. 1 issue of The Sp ...

Ebola death toll edging to 4,900 mark: WHO

7 hours ago

The death toll in the world's worst-ever Ebola outbreak has edged closer to 4,900, while almost 10,000 people have now been infected, new figures from the World Health Organization showed Wednesday.

US to track everyone coming from Ebola nations

7 hours ago

U.S. authorities said Wednesday that everyone traveling into the U.S. from Ebola-stricken nations will be monitored for symptoms for 21 days. That includes returning American aid workers, federal health employees ...

User comments